摘要
乳腺癌是一种激素依赖型肿瘤。雄激素受体在乳腺癌中表达率>70%,与新辅助化疗病理完全缓解率和预后密切相关。雄激素受体信号通路在不同乳腺癌亚型中增殖效应不同。多项抗雄激素受体临床试验正在进行,雄激素受体有望成为乳腺癌治疗新靶点。本文就雄激素受体在乳腺癌中信号通路、临床预后和治疗的研究进展作一综述。
Breast cancer is a kind of hormone-dependent tumor.Androgen receptor(AR)has a more than 70%expression rate in breast cancer,which is closely correlated with the pathologic complete response rate of neoadjuvant chemotherapy and prognosis.The AR signaling pathway has different proliferation effects on different breast cancer subtypes.Multiple anti-AR clinical trials are under way,and AR is expected to be a new target for breast cancer treatment.This paper reviews the signal pathway,clinical prognosis and treatment progress of AR in breast cancer.
作者
韦德飞
马青
张京伟
WEI De-fei;MA Qing;ZHANG Jing-wei(Department of Breast and Thyroid Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China)
出处
《中华实用诊断与治疗杂志》
2018年第6期618-621,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然基金面上项目(81472765)
关键词
乳腺癌
三阴性乳腺癌
雄激素受体
信号通路
Breast cancer
triple-negative breast cancer
androgen receptor
signaling pathway